INFO & CONTACTS:  +39 02 2390 1

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209)

Phase: Phase II clinical trials

Principal Investigator: Dott.ssa Giannatempo Patrizia

Main Facility: Oncologia Medica Genitourinaria

Drug: Enfortumab Vedotin, Pembrolizumab

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

Last update: 06/10/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe